Ποια είναι η τιμή για Jiangsu Recbio Technology Co., Ltd. (2179)

Η τιμή για Jiangsu Recbio Technology Co., Ltd. (2179) είναι $0.63963115

Ποια είναι η κεφαλαιοποίηση αγοράς για Jiangsu Recbio Technology Co., Ltd. (2179)

Η κεφαλαιοποίηση αγοράς για Jiangsu Recbio Technology Co., Ltd. (2179) είναι $339.16M

Jiangsu Recbio Technology Co., Ltd. (2179) Τιμή και Κεφαλαιοποίηση Αγοράς

Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.

Η τιμή για 2179	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$9,856.05 $339.16M	NVDA	$5.226T	+1,540,795.73%
$8,987.33 $339.16M	AAPL	$4.766T	+1,404,980.46%
$7,628.51 $339.16M	GOOG	$4.045T	+1,192,542.10%
$7,061.31 $339.16M	MSFT	$3.744T	+1,103,865.85%
$5,183.49 $339.16M	AMZN	$2.749T	+810,287.67%

Η τιμή για 2179

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$9,856.05 $339.16M